Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary

Cancer Treat Rep. 1976 Jan;60(1):55-60.

Abstract

Cis-dichlorodiammineplatinum(II) was used in the treatment of 34 patients with advanced adenocarcinoma of the ovary who were resistant to conventional chemotherapy. Two dose schedules were explored: a high-dose schedule with 30 mg/m2 given daily on 3 successive days every 4 weeks and a low-dose schedule with 30 mg/m2 given once every 2-3 weeks. Nine patients (26.5%) showed a therapeutic response with a median duration of 6 months (range, 3-15 months). The main toxic effects included myelosuppression, renal function impairment, and nausea and vomiting. The high-dose schedule proved to be more toxic without any therapeutic advantage.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Blood Platelets / drug effects
  • Cisplatin / therapeutic use*
  • Drug Administration Schedule
  • Female
  • Hemoglobins
  • Humans
  • Leukocyte Count
  • Leukocytes / drug effects
  • Middle Aged
  • Nausea / chemically induced
  • Ovarian Neoplasms / drug therapy*
  • Urea / blood
  • Vomiting / chemically induced

Substances

  • Antineoplastic Agents
  • Hemoglobins
  • Urea
  • Cisplatin